

REVIEW

Open Access



Epigenetic effects of herbal medicine

Yu-Yao Wu^{1†} , Yan-Ming Xu^{1†} and Andy T. Y. Lau^{1*}

Abstract

Epigenetic memory is essential for life that governs the predefined functional features of cells. Recent evidence has indicated that the epigenetic modification provides a potential link to gene expression changes that may be involved in the development of various chronic diseases, and targeting the epigenome becomes a plausible method for treating diseases. Traditional herbal medicine has gradually entered the vision of researchers due to its low toxicity and its effectiveness in treating diseases. As a matter of fact, researchers found that the possessed epigenetic modification capacity of herbal medicine had the ability to combat the progression of the disease, such as various types of cancer, diabetes, inflammation, amnesia, liver fibrosis, asthma, and hypertension-induced renal injury. Studies on the epigenetic effects of herbal medicine will provide valuable insights into the molecular mechanisms of human diseases, which may lead to new therapeutic approaches and diagnoses. Thus, this review summarized the impact of herbal medicine and its bioactive components on disease epigenome as examples of how utilization of epigenetic plasticity could be useful as the basis for the future development of targeted therapies in chronic diseases.

Keywords Herbal medicine, Epigenetics, Cancer, Chronic diseases

Background

Chronic diseases have now become a major health problem threatening to developing and developed countries, and if the situation is not effectively improved, the pandemic of chronic diseases will become a great burden to the global healthcare systems [1]. Sadly, most chronic diseases are difficult to cure, and patients can only take drugs to prevent the aggravation of the disease and delay the progress of the disease, such as cancer, coronary heart disease, diabetes and so on [2–4]. However, these drugs have more or less side effects, so understanding the pathogenesis of chronic diseases and finding appropriate therapeutic agents are urgently needed.

Epigenetic mechanisms play an important role in promoting the development of chronic diseases [5]. Epigenetic modifications mainly include DNA methylation, noncoding RNA, as well as histone modifications [6]. It has been found that noncoding RNA regulates gene transcription by inducing DNA methylation and histone modifications [7, 8]. DNA methylation and histone modifications are involved in many cellular processes and multiple human diseases [9]. Many substances can cause damage to the body by affecting the epigenetic state, resulting in the occurrence of chronic diseases. E-cigarettes ingredients (nicotine, tobacco-specific nitrosamines, volatile organic compounds, carbonyl compounds and toxic metals) can influence the occurrence of chronic bronchitis, facilitate cancer, neurodegeneration, etc., through DNA methylation, histone modifications or non-coding RNA expression [10]. Besides, epigenetic changes associated with cancer risk factors may play an important causal role in the development of cancer [11]. At the same time, disrupting the balance of epigenetic modifications within the body may lead to multiple pathologies, such as obesity and type 2 diabetes mellitus (T2D) [12]. Thus, a compromised epigenetic state plays a pivotal

Yu-Yao Wu and Yan-Ming Xu contributed equally to this work.

*Correspondence:

Andy T. Y. Lau
andytylau@stu.edu.cn

¹ Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou 515041, Guangdong, People's Republic of China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

role in contracting various diseases, while the reversal of aberrant epigenetic modifications provides an exciting opportunity for the development of clinically relevant therapies [13].

Traditional Chinese Medicine (TCM) has a long history in China and TCM is an important category of complementary and alternative medicine, its use has increased in place in western countries over the past decade and the typical TCM therapies include acupuncture, herbal medicine and qigong exercises [14]. The three most common diseases of TCM users were tumors (33.2%), respiratory diseases (32.9%) and infectious diseases (8.86%), while the most commonly used TCM therapy is the Chinese herbal medicine and patients with comorbid diseases such as allergic rhinitis, indigestion, menstrual disorders, musculoskeletal system and connective tissue disorders tend to visit TCM clinics [15]. Studies have also indicated that herbal medicine can influence the progression of diseases through epigenetic modifications, including cancer, Alzheimer's disease, male infertility, etc. [16–18].

Understanding the regulation of the human epigenome by herbal medicine can help to elucidate the discovery of plant pharmacology and epigenetic drugs [19]. Therefore, this review mainly combines the relevant literature of nearly 10 years to discuss the epigenetic modification of chronic diseases through DNA and histone modifications by herbal medicine, in order to provide ideas for future disease research and treatment.

Bioactive compounds from herbal medicine

Herbal medicine has been serving the Chinese people since ancient times and plays an important role in today's medical care [20]. According to a 1995 survey, there are 12,807 Chinese medicinal resources in China, including 11,146 medicinal plants [21]. TCM is mainly composed of botanical medicine (root, stem, leaf, and fruit) and mineral medicine. Because plant medicine accounts for the majority of TCM, TCM is also called herbal medicine. Although Western medicine has achieved remarkable results in the treatment of many diseases, the main challenges remain: infectious diseases that rapidly evolve to develop drug resistance to drugs, new diseases, especially new diseases caused by viruses, and ineffective long-term treatment of chronic and non-communicable diseases. TCM can provide complementary treatment based on personalized interventions to address the impact of disease on the whole body [22]. Most of the TCM preparations are oral preparations, such as decoction, pills, powder and other TCM dosage forms, as well as modern dosage forms such as granules, tablets and capsules. The oral preparations of TCM are the same as the chemical drug preparations containing one or more active ingredients, which first need to be absorbed through the gastrointestinal tract.

TCM is rich in various components, leading to the complex absorption mechanism of drugs in the gastrointestinal tract, which is also one of the main differences between TCM and chemical drugs [23]. Although each herbal medicine contains hundreds or even thousands of components, only a few compounds can produce the drug and/or toxic effects [24]. Table 1 shows the active components with epigenetic modification effects as well as plants that are currently known to acquire these components. The active ingredients are rich in different herbs, which give these plants the characteristics to treat different diseases. Based on the efficacy of many bioactive compounds first discovered in herbal extracts, such as paclitaxel, camptothecin, and artemisinin, more people are accepting herbal medicine as potential sources of clinical drugs [25].

Epigenetic mechanism of herbal medicine

DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) are associated with the occurrence and progression of human malignancies, and DNMT and HDAC inhibitors are currently being explored as anticancer drugs in clinical trials [57, 58]. DNMTs can mediate specific DNA methyl transfer leading to epigenetic silencing of multiple genes [59]. HDACs catalyze the deacetylation of lysine residues in the N-terminal tail of histone proteins and regulate the expression of related genes [60]. Regulating the expression or activity of DNMT and HDAC is the most common way that herbal medicine and its bioactive components combating the disease through epigenetic regulation. In addition to these, as shown in Fig. 1, herbal medicine can also regulate the expression of related genes by affecting histone methylation, acetylation, phosphorylation, ubiquitination, as well as the demethylation modification of DNA.

Brain tumor

There are about 120 types of brain tumors, about 45% of the primary brain tumors are glioma, and glioma or astrocytoma is one of the most common and aggressive brain tumors in children and adults [61]. For these cancers, very few effective treatment methods, even after active surgery, chemotherapy and radiotherapy, the patient survival rate is still very low [62].

Since 2014, Skala and Sitarek et al. have investigated the effects of Chinese herbal medicine on glioma, and initially they found that *Leonurus sibiricus* transgenic roots and *Rhaponticum carthamoides* transformed root are able to promote glioma cell apoptosis and inhibit their viability. Poly ADP-ribose polymerase 1 (PARP1) cleavage increasing γ H2A.X histone levels is necessary for the repair of DNA double-strand breaks and maintenance of genomic stability [63]. While Ubiquitin-like with plant homeodomain and ring-finger domains 1 (UHRF1) and DNMT1 are capable

Table 1 Major active components with epigenetic modification effects from different herbal medicine














Active component	Chemical structure	Source plant		References
		Latin name	Common name	
Allicin		<i>Allium sativum</i>	Garlic	[26]
Baicalin		<i>Scutellaria baicalensis</i>	Chinese skullcap	[27]
Calebin-A		<i>Curcuma longa</i>	Turmeric	[28]
Cannabidiol		<i>Cannabis sativa</i>	Hemp	[29]
Cannabigerol		<i>Cannabis sativa</i>	Hemp	[29]
Cucurbitacin B		<i>Trichosanthes cucumerina</i>	Snake gourd	[30]
Curcumin		<i>Curcuma longa</i>	Turmeric	[31]
Curcumol		<i>Curcuma kwangsiensis</i>	Curcuma rhizoma	[32]
Esculetin		<i>Citrus limonia</i> , <i>Cortex fraxini</i> , <i>Cerato-stigma willmottianum</i>	Lemon leaf, Ash bark, Chinese plum-bago	[33]
Hesperetin		<i>Citrus</i>	Citrus fruits	[34]
Hydroxysafflor yellow A		<i>Flos carthami</i>	Safflower	[35]
Juglanin		<i>Polygonum aviculare</i>	Bianxu	[36]
Kazinol Q		–	Formosan plant	[37]

Table 1 (continued)




















Active component	Chemical structure	Source plant		References
		Latin name	Common name	
Kaempferol		<i>Cucurbita maxima</i> , <i>Daucus carota</i> , <i>Ginkgobiloba</i> , <i>Pinus densiflora</i> , <i>Angelicaedecursiva</i> , etc	Pumpkin, Carrot, Ginkgo, Japanese red pine, etc	[38]
Luteolin		<i>Apium graveolens</i> , <i>Capsicum annuum</i> , <i>Perilla frutescens</i> , <i>Camellia sinensis</i>	Celery, Green pepper, Perilla leaf, Chamomile tea	[39]
Moringa isothiocyanate		<i>Moringa oleifera</i>	Drumstick tree	[40]
Naringenin		<i>Aurantii fructus</i>	Immature trifoliolate-orange fruit	[41]
N-butylidenephthalide		<i>Angelica sinensis</i>	Danggui	[42]
Nimbolide		<i>Azadirachta indica</i>	Neem	[43]
Nordihydroguaiaretic acid		<i>Larrea tridentata</i>	Creosote bush	[44]
Oleanolic acid		<i>Oleaceae</i>	Oleaceae family plants	[45]
Osthole		<i>Cnidium monnieri</i>	Shechuangzi	[46]
Parthenolide		<i>Tanacetum parthenium</i>	Feverfew	[47]
Piperine		<i>Piper nigrum</i>	Black pepper	[48]
Sennoside A		<i>Rheum rhabarbarum</i>	Rhubarb	[49]
Silibinin		<i>Silybum marianum</i>	Milk thistle	[50]

Table 1 (continued)

Active component	Chemical structure	Source plant		References
		Latin name	Common name	
Tanshinone I		<i>Salvia miltiorrhiza</i>	Danshen	[51]
Tetramethylpyrazine		<i>Chuanxiong rhizoma</i>	Chuanxiong	[52]
Triptolide		<i>Tripterygium wilfordii</i>	–	[53]
Valeric acid		<i>Valeriana officinalis</i>	Valerian	[54]
Zaluzanin D		<i>Gymnanthemum cass</i>	Vernonia arborea	[55]
Z-ligustilide		<i>Chuanxiong rhizoma</i>	Chuanxiong	[56]

of epigenetic regulation of histone ubiquitination and DNA methylation [64]. Through further studies, they found that the cell-induced anticancer effects of *Leonurus sibiricus* extracts were associated with the number of γ H2A.X and cleaved PARP1, and the level of UHRF1 and DNMT1 [65]. At the same time, *Rhaponticum carthamoides* extract can also trigger apoptosis in glioma cells by inducing DNA damage, PARP cleavage and epigenetic modification [66]. Topoisomerase II β (TopoII β) is a ribozyme that plays an important role in neuronal development. Yan et al. [52] conducted chromatin immunoprecipitation analysis and found that tetramethylpyrazine enhanced the recruitment of ac-H3 and ac-H4 in the promoter region of the *TopoII β* gene. Therefore, herbal medicine can also promote high TopoII β expression through epigenetic regulation and stimulate the neuronal differentiation of SH-SY5Y cells.

Thoracic tumor

Thoracic malignancies include some of the most common and lethal cancers. It is expected that in the near future, the increase in cancer mortality is mainly related to smoking-induced lung cancer (including men and women), and female breast cancer [67]. In the 2008 study, tanshinone I showed the potential as an effective adjuvant in the treatment of human breast cancer, which effectively inhibited the proliferation of breast cancer cells MCF-7 and MDA-MB-231 while promoting its apoptosis [68]. Aurora A is a potential tumor

marker, which is mainly localized to the spindle poles and the mitotic spindle, regulating the function of centrosomes, spindle bodies and kinetochores required for the normal progression of mitosis [69]. Inhibition of Aurora A directly reshaped the immune microenvironment by removing tumor-promoted myeloid cells and enriching anticancer T lymphocytes, which established a tumor-suppressive microenvironment and significantly promoted mammary tumor regression in mice [70]. In 2012, Gong et al. [71] showed that tanshinone I may downregulate *Aurora A* gene expression by reducing the ac-H3 associated with the primer 4-amplified area in the DNA promoter of the *Aurora A* gene, so inhibit the growth of breast cancer cells. In addition, herbal medicine can also affect the proliferation of breast cancer cells through the epigenetic regulation of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that play a key role in cancer progression and metastasis [72]. The AKT/mTOR signaling pathway regulates the H3K27ac and H3K56ac, and Wu et al. [73] treated the cells with luteolin and found the levels of p-AKT and mTOR proteins were significantly reduced, thus increasing the overall occupancy levels of H3K27ac and H3K56ac in the MMP-2 and MMP-9 promoter regions, significantly inhibiting the expression of MMPs. At the same time, they also found luteolin increased the overall levels of H3K4me1 in MCF7-TamR cells, and decreased the overall levels of H3K4ac, which enhances H3K4me1 occupancy to the




Fig. 1 Epigenetic molecular targets of herbal medicine in cells. Herbal medicine can regulate histone methylation, histone acetylation and DNA methylation by affecting cellular factors directly, which are respectively located in the yellow, pink and orange patterns of the picture. Besides, herbal medicine can also affect histone ubiquitination and phosphorylation

Ras gene family promoter and suppresses its expression [74]. Besides, oncogenes play an important role in tumor development. After treating the breast cancer cells with cucurbitacin B isolated from the traditional herbal medicine *Trichosanthes cucumerina*, Dittharot et al. [30] found that cucurbitacin B can upregulate DNMT1 and hypermethylation in *c-Myc*, cyclin D1 and survivin promoters, thereby downregulating the expression of all these oncogenes. Thus, cucurbitacin B has proven to be a potential cancer therapeutic, in part through the induction of hypermethylation and silencing of oncogenic activation. Herbal medicine is also able to epigenetically regulate the development of lung cancer. Lu et al. [75] have used Jinfukang (JFK), a clinical medicine usually used to treat lung cancer, to investigate whether the epigenetic modification is involved in its anticancer activity. The results showed that A549 cells treated for 48 h with JFK reduced the H3K4me3 modification levels of *SUSD2*, *PTN*, *GLIS2*, *CCND2*, *TM4SF4*, *BCL2A1*, *IL31RA*, *WISP2*, *TNFAIP6* and *TMEM158* genes. Besides, *MYC* and *EGFR*, two genes known to have high levels of H3K4me3 in A549 cells, also showed a significantly reduced degree of H3K4me3 expression after JFK treatment. From these studies, we can see the potential of herbal medicine for therapeutic use for thoracic cancer.

Digestive system tumor

Digestive system cancer mainly consists of esophageal cancer, stomach cancer, small intestine cancer, colon-rectum cancer, liver, and pancreatic cancer. The incidence and mortality of digestive system cancer are very high, most of which are highly related to genetics and lifestyle [76]. In 2019, Li et al. [77] found that oleanolic acid, widely found in oleaceae family, inhibited the proliferation of human MKN-45 and SGC-7901 cells. Through further studies, in 2021, they identified epigenetic regulation of gastric cancer. Since immunotherapy through programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade has shown benefits for gastric cancer, epigenetic DNA methylation critically modulates cancer immune checkpoints. They stimulated human gastric cancer MKN-45 cells with interleukin-1 β (IL-1 β) and significantly increased PD-L1 expression. After treating cells with oleanolic acid the IL-1 β -increased DNA demethylase activity was abolished in MKN-45 cells, and oleanolic acid selectively reduced the expression of DNA demethylase tet methylcytosine dioxygenase 3 (TET3) induced by IL-1 β , and overexpression of TET3 restored oleanolic acid-reduced PD-L1 expression. Their findings suggest the potential of oleanolic acid as an epigenetic modulator of immunotherapy or adjunctive therapy of gastric cancer [45]. In the same year, in mice, the epigenetic regulation of herbal

medicine in gastric cancer was also found. One week after subcutaneous inoculation of MKN-45 cells in nude mice and gavage with hesperetin revealed that the levels of H3K79me2 and H3K79me3 were significantly reduced after hesperetin treatment. Moreover, the DOT1-like histone lysine methyltransferase (DOT1L) expression was also significantly decreased in vivo, and DOT1L is the only known H3K79 methyltransferase and can regulate cancer metastasis. To further confirm the effect of DOT1L on gastric cancer cell metastasis in vivo, MKN-45 cells were seeded into immunodeficient mice by tail vein injection. It was observed that downregulation of the *DOT1L* gene significantly inhibited the ability of MKN-45 cells to metastasize within the lung [78]. Thus, hesperetin targeting DOT1L may translate into future cancer treatment strategies. The *p16* gene belongs to the *INK4* gene family and consists of four members: p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D). They all have common biological characteristics, namely cell growth suppression and tumor suppression, and p16 is the second most common tumor suppressor gene after p53 [79]. Supercritical CO₂ extract of *Azadirachta indica* and nimbolide inhibited the expression of HDACs and DNMTs and significantly upregulated the acetylation levels of H3K9, H3K14, H3K18 and H3K27 in the p16 promoter region in HCT116 [80]. The p16 protein is inactivated in a variety of human cancers. Thus enhanced acetylation of the p16 promoter while reducing p16 methylation, both contribute to the restoration of *p16* gene expression, thereby affecting the expression of genes associated with cancer progression or repression that may be important targets for chemoprevention or therapy.

Urogenital tumor

Although cancer drugs have been evolving in recent decades, the incidence and mortality of the most prevalent urogenital cancers have not been significantly reduced [81]. Prostate cancer is the second most common cancer in men [82]. Since 2013, Tamgue et al. [83] began epigenetic studies of triptolide on prostate cancer. They treated the prostate cancer cells with triptolide and found that triptolide significantly inhibited the proliferation of prostate cancer and was also able to reduce enhancer of zeste homolog 2 (EZH2) expression. EZH2 is the enzymatic catalytic subunit of the polycomb repressor complex 2 and can alter the expression of downstream target genes by H3K27me3 [84]. Besides, there is evidence that EZH2 plays an important role in cancer initiation, development, progression, metastasis, and drug resistance [85]. Then, in a 2017 study, Tamgue and Lei [86] found that although triptolide reduced EZH2 expression in PC-3 cells, the levels of H3K27me3 and histone

H3 were increased. Therefore, other regulatory mechanisms may exist in PC-3 cells. Thus, they further found that the levels of mRNA and protein of UTX (also known as KDM6A) and histone demethylase Jumonji domain-containing 3 (JMJD3), which regulate H3K27me3 demethylation [87], decreased significantly in a dose- and time-dependent manners. Meanwhile, triptolide significantly increases the protein levels of SUV39H1, a histone methyltransferase that catalyzes the methylation of H3K9 [88], and related H3K9me3. In addition, they found that triptolide-induced deposition of H3K9me3 at the target gene promoters was highly SUV39H1-dependent and that inhibition of gene expression was partly mediated by enhancing the deposition of the H3K9me3 at gene promoter and inducing heterochromatin formation. These show the great clinical application value of triptolide. Besides, it has been found that components in herbal medicine can epigenetically regulate NRF2, a master regulator of many critical anti-oxidative stress defense genes in human prostate cancer [89], to regain their expression [90]. Lysine demethylase 1B (KDM1B) is a histone H3K4 demethylase required to establish maternal genomic imprints [91]. Lee et al. [92] found that *Oldenlandia diffusa* extract, by regulating KDM1B, effectively promoted the death of cisplatin-resistant ovarian cancer cells treated with cisplatin. However, the specific mechanism is still unclear and requires further experimental exploration.

Blood tumor

Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most common hematological cancer after non-Hodgkin's lymphoma. Malignant transformation of plasma cells gives them the ability to proliferate, causing harmful lesions to the patients [93]. The epigenetic studies on herbal medicine for myeloma were mainly conducted with triptolide by Wen et al. In 2010, using multiple myeloma cell line U266, it was found that triptolide dose-dependently reduced the genome-wide H3K4me3, H3K27me3, and H3K36me3, while also inhibiting SMYD3, EZH2 and nuclear receptor binding SET domain protein 1 (NSD1) expression [53]. Among them, SMYD3 is a SET domain-containing protein that has histone methyltransferase activity on histone H3K4, and SMYD3 is frequently overexpressed in different cancer cell types [94], which is associated with advanced stage and poor survival [95]. NSD1 is a bifunctional transcriptional regulatory protein able to participate in the regulation of mono- and dimethylation of H3K36, and targeting NSD1 may be a potential strategy for tumor therapy [96, 97]. Then, in 2012, by studying multiple myeloma (MM) cells, triptolide was demonstrated to decrease the overall H3K4me2 and

H3K36me2 levels in a dose-dependent manner [98]. It also significantly increased the expression of lysine-specific histone demethylase 1 (LSD1), a nuclear histone demethylase [99], and decreased the JMJD2B expression which is a histone demethylase enzyme that regulates gene expression through demethylation of H3K9me3 and H3K36me2 [100, 101]. Lastly, in 2015, Wen et al. [102] treated KM3 cells with triptolide, and the results showed that triptolide can downregulate the expression of the proto-oncogenes *c-Myc* and *VEGFA*, a principal angiogenic factor essential for angiogenesis [103], by blocking the accumulation of H3K4me3 at its promoter. These results suggest that herbal medicine may have a strong effect against MM through epigenetic mechanisms. In addition, herbal medicine can regulate epigenetic regulation of leukemia and inhibit its development. Wang et al. [56] found that *z-ligustilide* increased the level of ac-H3 (K9/14) in HL-60 cells and enriched ac-H3 (K9/14) in the promoter region of *Nur77* and *NOR-1*. At the same time, it significantly increased p300 acetyltransferase and decreased HDAC, including HDAC1 and HDAC4/5/7 and transfer-related protein 1, recruitment to the *Nur77* promoter region. *Z-ligustilide* also enriched p-CREB in the *NOR-1* promoter region, while HDAC1 and HDAC3 decreased in the *NOR-1* promoter region. Thus, herbal medicine has strong potential in treating acute leukemia through epigenetic regulation.

Other chronic diseases

Herbal medicine also plays an important role in the epigenetic regulation of the development of other diseases, such as diabetes, inflammation, liver fibrosis, obesity, amnesia, and so on. In a 2015 study, the function of *esculetin* in diabetes was identified by Kadakol et al. [104]. Posttranslational histone modifications (PTHMs) play a key role in the pathogenesis of diabetic complications [105]. They found that the treatment of hearts of IR and type 2 diabetic rats with *esculetin* reduced the originally elevated H3K4me2, H3K36me2, H3K79me2, H3S10ph, H3S28ph, H3T3ph, H3K27ac, H3K56ac, H2AK119ub, and H2BK120ub [106]. In 2017, it was demonstrated that *esculetin* treatment significantly improved vascular reactivity, increased eNos and decreased *Vcam1* mRNA levels, and reduced collagen deposition in the rat thoracic aorta. At the same time, it can further improve vascular perturbation by reversing H2BK120ub to occupy the promoters of the *At1*, *At2*, *Tgfb1*, and *Mcp1* genes [33]. In the same year, they also found that *esculetin* and *telmisartan* in combination therapy could improve type 2 diabetic cardiomyopathy by reversing H3, H2A, and H2B histone modifications [107]. These studies suggest that *esculetin* can be used as an advanced therapeutic agent, which may be partly attributed to its ability to reverse epigenetic

alterations. Liver fibrosis occurs due to the long-term injury caused by the activated myofibroblast-mediated excessive wound healing response and the excessive scar deposition in the liver parenchyma. Although genetic effects are important, epigenetic mechanisms have been shown to orchestrate many aspects of liver fibrogenesis [108]. In 2020, by studying HSC-T6, *sennoside A* was demonstrated to reduce the expression of cyclin D1, CDK and *c-myc* and significantly inhibit the expression of p-AKT and p-ERK as well as α -smooth muscle actin and type I collagen alpha-1 protein levels. Meanwhile, *sennoside A* can directly bind to DNMT1 and inhibit its activity, thus significantly promoting phosphatase and tension homolog deleted on chromosome 10 (PTEN) expression in vitro [109]. However, the dynamic expression of PTEN in rat liver tissue was negatively correlated with liver fibrosis and activated hepatic stellate cells, and positively with the reversal of fibrosis and apoptotically activated hepatic stellate cells [110]. It thus follows that the epigenetic regulation of PTEN expression by *sennoside A* may be an effective new method for the treatment of liver fibrosis. In 2021, using the same cell line as with the animal model, it was shown that *sennoside A* consistently inhibits the expression of the liver fibrogenesis markers α -smooth muscle actin and type I collagen alpha-1 and suppresses the inflammatory response in vitro and in vivo. It can also promote SOCS1 expression in a DNMT1-dependent manner [49]. Besides, SOCS1 helps to protect against liver injury and fibrosis and may also protect against liver carcinogenesis [111].

All of the above information is integrated into Table 2.

Conclusions

Herbal medicine has a strong capacity to regulate the occurrence and progression of chronic diseases through epigenetics. In tumors, herbal medicine can regulate the expression of tumor-related genes by influencing the methylation and acetylation of histones at the gene promoter or enhancer by controlling the expression of CBP, SUV39H1, EZH2, JMJD3, UTX, NSD1, etc. At the same time, herbal medicine can also regulate the methylation of DNA by affecting the expression of TET3, UHRF1, DNMTs, etc. In epigenetic studies of other diseases, herbal medicine shows the great potential of clinical applications in treating amnesia, allergic asthma, diabetes, inflammation, and liver fibrosis. However, the study of the specific mechanism is still quite limited. In order to provide more comprehensive information on the epigenetic impact of herbal medicine on human diseases and to fully exploit its potential in the clinic, further well-designed in vivo studies should be conducted.

Table 2 Herbal medicine-induced epigenetic alterations on chronic diseases

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2013	Curcumin	U87 and U251 cells	DNA	•30 µM curcumin for 4 days •10, 20, and 40 µM curcumin for 4 days	•Curcumin induces hypomethylation at 17 CpG sites on the RANK promoter •Curcumin inhibits the activity of DNMT1	Results in RANK gene activation in epigenetic modification in human glioblastoma cells	[31]
2014	Tetramethylpyrazine	SH-SY5Y cells	Histone	•80 µM tetramethylpyrazine for 3 or 5 days	•Tetramethylpyrazine enhances the recruitment of ac-H3 and ac-H4 to the <i>TopoIIβ</i> gene promoter region	Promotes SH-SY5Y cells to differentiate toward post-mitotic neurons	[52]
2018	<i>Leonurus sibiricus</i> transgenic roots extract	U87MG and grade IV glioma cells	DNA; Histone	•Treat the cells with the extraction for 24 h	•The extract downregulates the expression of UHRF1 and DNMT1	Influences epigenetic regulation	[65]
2018	<i>Rhaponticum carthamoides</i> transformed roots extract	U87MG and grade IV glioma cells	DNA; Histone	•Treat the cells with the extraction for 24 h	•The extract downregulates the expression of UHRF1 and DNMT1	Influences epigenetic regulation	[66]
2019	Calebin-A	STS26T, ST8814, T265, and S462-TY cells	Histone	•12.5 and 25 µM calebin-A •Calebin-A for 8 or 24 h	•Calebin-A decreases H3 histone acetylation •Reduces HAT activity	Epigenetic control of <i>survivin</i> and <i>hTERT</i> genes	[28]
2008	Nordihydroguaiaretic acid	T47D and RKO cells	DNA	•0–100 µM nordihydroguaiaretic acid for 72 or 144 h	•Nordihydroguaiaretic acid reverses p16INK4a CpG island hypermethylation	Induces cell cycle arrest in the G1 phase and a senescence-like state in cells	[112]
2008	Nordihydroguaiaretic acid	SKBR3 and MDA-MB-435 cells	DNA	•0–100 µM nordihydroguaiaretic acid for 7 days	•Nordihydroguaiaretic acid reverses methylation-silenced <i>E-cadherin</i> gene hypermethylation	Reactivates the expression of <i>E-cadherin</i>	[44]
2012	<i>Thymus serpyllum</i> extract	MDA-MB-231 cells	DNA; Histone	•250 and 500 µg/mL extract for 72 h	•The extract inhibits the DNMT and HDAC activities	Influences epigenetic regulation	[113]
2012	Tanshinone I	MCF-7 cells	Histone	•3 µM tanshinone I for 48 h	•Tanshinone I reduces ac-H3 associated with the primer 4-amplified area in <i>Aurora A</i> gene DNA promoter	Downregulates <i>Aurora A</i> gene expression	[71]
2014	Kazinol Q	MDA-MB-231 cells	DNA	•1, 2.5, 5, and 10 µM kazinol Q for 48 h	•Kazinol Q inhibits DNMT1 activity and reactivates the expression of a DNA methylation-silenced gene, <i>E-cadherin</i>	Inhibits cell viability	[37]
2016	Tien-Hsien Liquid	MCF-7 cells	DNA	•0–6 mg/mL Tien-Hsien Liquid for 72 h	•Tien-Hsien Liquid downregulates the protein level of DNMT1 and DNMT3a	Influences epigenetic regulation	[114]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2016	Jinfukang	A549 cells	Histone	•Treat the cells with Jinfukang for 48 h	•Jinfukang downregulates the H3K4me3 modification levels at <i>SUSD2</i> , <i>PTN</i> , <i>GLI2</i> , <i>CCND2</i> , <i>MYC</i> , <i>EGFR</i> , and <i>TM4SF4</i> genes, whereas those at <i>BCL2A1</i> , <i>IL31RA</i> , <i>WISP2</i> , <i>TNFAIP6</i> , and <i>TMEM158</i> genes are upregulated	Inhibits cell proliferation	[75]
2017	Z-ligustilide	MDA-MB-231 cells	Histone	•50 µM Z-ligustilide for 72 h	•Z-ligustilide increases the enrichment of ac-H3 (K9/14) in the ERα promoter, and significantly reduces HDAC1, HDAC2, and HDAC4/5/7 at the ERα promoter	Induces cell cycle arrest and apoptosis	[115]
2018	Nimbolide	MDA-MB-231 and MCF-7 cells	Histone	•0–2.5 µM nimbolide for 48 h	•Nimbolide decreases HDAC2 and increases H3K27ac	Induces apoptosis, autophagy, cytoplasmic vacuolization and formation of autophagosomes	[43]
2019	Cucurbitacin B	MDA-MB-231, MCF-10A, and MCF-7 cells	DNA	•0–5 µM cucurbitacin B for 48 h	•Cucurbitacin upregulates DNMT1, as well as increases methylation in c-Myc, cyclin D1, and survivin promoters	Downregulates the expression of oncogenes, c-Myc, cyclin D1, and survivin	[30]
2020	Luteolin	MCF7-TamR cells	Histone	•10 and 20 µM luteolin	•Luteolin increases the expression of MLL3, increases the global level of H3K4me1, decreases the global level of H3K4ac, and increases the monomethylation level of H3K4 in the <i>Ras</i> gene enhancer and promoter region	Inactivates PI3K/AKT/mTOR pathway through repression of the <i>Ras</i> gene and thus causes apoptosis in tamoxifen-resistant breast cancer cells	[74]
2020	<i>Cotinus cogglyria</i> Scop. extract	MCF-7 cells	DNA	•40.6 µg/mL <i>Cotinus cogglyria</i> Scop. extract for 3, 24, 48, or 72 h	•Inhibits the expression of DNMT1 and DNMT3a	Causes S phase cell cycle arrest and triggers apoptosis, reduces colony formation, induces DNA damage, affects cellular thermodynamic parameters	[116]
2021	Valeric acid	MCF-7 cells	DNA; Histone	•0–10 µM valeric acid for 48 h	•Reduces HDAC activity and a global DNA hypomethylation	Decreases the breast cancer cell proliferation	[54]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2021	Luteolin	BT-20 and MDA-MB-231 cells	Histone	•10, 20 and 30 μM luteolin	•Luteolin decreases the level of H3K27ac and H3K56ac in the MMP-9 promoter region 2 and 3 in the BT-20 cells, and increases H3K27ac and H3K56ac on the MMP-2 and MMP-9 promoter region in MDA-MB-231 cells	Inhibits the proliferation and metastasis of androgen receptor-positive triple-negative breast cancer cells	[73]
2010	Digestive system tumor <i>N</i> -butylidenephthalide	HepG2 and J5 HCC cells	DNA	•50 $\mu\text{g}/\text{mL}$ of <i>n</i> -butylidenephthalide for 48 h •25 $\mu\text{g}/\text{mL}$ <i>n</i> -butylidenephthalide combined with 6.25–25 μM 1,3-bis(2-chloroethyl)-1-nitrosourea for 48 h	• <i>N</i> -butylidenephthalide downregulates the mRNA and protein level of MGMT •The combination treatment enhances methylation of the MGMT promoter	Inhibits the expression of MGMT and enhances apoptosis	[42]
2019	<i>Ginkgo biloba</i> extract	B6C3F1/N mice	DNA	•0, 200, 600, and 2000 mg/kg <i>Ginkgo biloba</i> extract, 5 days a week for 104 weeks	•The <i>Ginkgo biloba</i> extract-exposed affects the methylation of the hepatocellular carcinoma gene promoter	Influences epigenetic regulation	[117]
2019	Aged citrus peel extract	AML-12 cells	DNA; Histone	•0–100 $\mu\text{g}/\text{mL}$ aged citrus peel extract for 72 h •50–1000 $\mu\text{g}/\text{mL}$ aged citrus peel extract	•Aged citrus peel extract decreases the protein expression of HDAC8, DNMT1 and DNMT3a, enhances the protein expression of JMJD3 and UTX, and demethylates Nrf2 promoter •Inhibits CpG methyltransferase activity	Attenuates APAP-induced hepatic injury through the reactivation of NRF2 pathway in mouse AML-12 hepatocytes	[118]
2019	Supercritical CO ₂ extract of <i>Azadirachta indica</i> ; Nimbolide	HCT116 and HT29	DNA; Histone	•40 and 75 $\mu\text{g}/\text{mL}$ supercritical CO ₂ extract of <i>Azadirachta indica</i> for 48 or 96 h •5 and 10 μM nimbolide for 48 or 96 h	•Inhibits HDAC and DNMT activity and expression in both cell lines •Increases acetylation of H3K9, H3K14, H3K18, and H3K27 in the p16 promoter region and decreases methylation levels of H3K9me3 and H3K27me3 in HCT116 cells	Restores the expression p16	[80]
2020	Silibinin	RT4, 5637, and T24 cells	DNA	•50 μM silibinin for 24 h	•Silibinin induces global DNA hypomethylation	Influences epigenetic regulation	[50]
2020	Valeric acid	Hep3B, SNU-449, and HepG2 cells	Histone	•850 μM valeric acid for 24, 48, or 72 h	•Valeric acid inhibits HDAC1, HDAC2 and HDAC3 activity	Suppresses liver cancer development	[119]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2021	Oleanolic acid	MKN-45 cells	DNA	-0–40 µM oleanolic acid for 24 h		<ul style="list-style-type: none"> •Oleanolic acid selectively reduced the expression of TET3 in IL-1β-treated MKN-45 cells 	Leads to DNA hypomethylation	[45]
2021	Hesperetin	Nude mice with MKN45 cells MKN-45 and HGC-27 cells	Histone	<ul style="list-style-type: none"> •Mice: 50 mg/kg hesperetin for 1 week •Cell: 0–100 µM hesperetin for 48 h 		<ul style="list-style-type: none"> •Hesperetin decreases H3K79me2 and H3K79me3 levels in mice •Inhibits H3K79 methylation and reduces the abundance of Dot1L protein in the cells 	Decreases the mobility of gastric cancer cells and inhibits the abundance of DOT1L	[78]
2021	Curcumin	HepG2 and SMMC-7721 cells	Histone	-60 µM curcumin for 48 h		<ul style="list-style-type: none"> •Curcumin increases the expression of H3K27me3 and H3K9me3 in HepG2 cells, decreases H3K27me3 expression in SMMC-7721 cells, and downregulates EZH2 	Downregulates lncRNA Hotair in turn downregulated EZH2, thereby disrupting trimethylation of H3K9 and H3K27 specifically catalyzed by EZH2, and regulating histone modification to inhibit tumor growth and metastasis	[32]
2022	Baicalin	BALB/c nude mouse and HepG2 cells	DNA	<ul style="list-style-type: none"> •Mice: 20 or 50 mg/kg baicalin for 28 days •Cell: 50 mg/L baicalin for 24 h 		<ul style="list-style-type: none"> •Baicalin downregulates the m6A/A, SAM/SAH, and m6A (2854) levels of HKDC1 in the tumor tissue of the BALB/c mice •Downregulates the total DNA 5mC and RNA m6A levels, upregulates SAM/SAH, and suppresses the RNA m6A (2854) of HKDC1 in HepG2 cells 	Inhibits the progression of T2D-induced liver tumors by regulating the HKDC1/JAK2/STAT1/caspase-3 pathway	[27]
2022	<i>Phyllanthus debilis</i> methanolic extract	HT-29 cells	DNA	-0.1 mg/mL <i>Phyllanthus debilis</i> methanolic extract for 24 h		<ul style="list-style-type: none"> •<i>Phyllanthus debilis</i> extract increases the Alu DNA methylation and LINE-1 methylation 	Anticancer effects	[120]
Urogenital tumor	Trichosanthin	HeLa and CaSki cells	DNA	-0, 20, 40, and 80 µg/mL for 48 h		<ul style="list-style-type: none"> •Trichosanthin inhibits DNMT1 enzyme activity and DNMT1 expression 	Induces gene demethylation of both HeLa and CaSki cells	[121]
2012	Triptolide	Du145	Histone	-0, 25, 50, 100 nM triptolide for 24 h		<ul style="list-style-type: none"> •Triptolide decreases histone H3K27me3 methylation and downregulates EZH2 	Influences epigenetic regulation	[122]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2013	Z-Ligustilide; Radix Angelicae Sinensis	TRAMP C1 cells	DNA	•50 µM Z-Ligustilide or 8.5 µg/mL Radix Angelicae Sinensis for 3 days	•Z-Ligustilide or Radix Angelicae Sinensis treatment reduces the methylation levels of the first five CpG of the NRF2 promoter and inhibits DNA methyltransferase in vitro	Results in the re-expression of NRF2 and NRF2 target genes	[90]
2013	Triptolide	PC-3 cells	Histone	•0–1 µM triptolide for 24 h	•Triptolide decreases the expression of EZH2	Results in increased mRNA levels of target genes (ADRB2, CDH1, CDKN2A, and DAB2IP), and decreased mRNA levels of gene (cyclinD1)	[83]
2014	Zyflamend	CWR22Rv1 cells	Histone	•200 µg/mL zyflamend for 0–60 min •200 µg/mL zyflamend for 24 h	•Zyflamend downregulates the expression of all class I and II HDACs, and upregulates the histone acetyltransferase complex CBP/ p300 •Increases histone 3 acetylation	Promotes the increased expression of the tumor suppressor <i>p21</i> gene	[123]
2015	Allicin	MIA PaCa-2 cells	Histone	•100 and 200 µM allicin for 24 h	•Allicin reduces the level of H3K9me, and increases the level of H3S10ph and H3K14ac	Modulates apoptosis and represses gene expression	[26]
2017	Triptolide	PC-3 cells	Histone	•0–100 nM triptolide for 24 h or 100 nM triptolide for 0–24 h	•Triptolide enhances H3K27me3 levels by downregulating JMJD3 and UTX and enhances H3K9me3 level through upregulation of SUV39H1	Influences epigenetic regulation	[86]
2019	<i>Oldenlandia diffusa</i> extract	A2780cis cells	Histone	•40 µg/mL and 160 µg/mL for 48 h	• <i>Oldenlandia diffusa</i> extract downregulates the epigenetic regulator KDM1B	Overcomes resistance to cisplatin in CRC by modulating epigenetic regulation	[92]
Blood tumor							
2010	Triptolide	U266 cells	Histone	•20, 80, and 160 nM triptolide for 48 h •20, 80, and 160 nM triptolide for 24 h	•Triptolide decreases the expression of histone H3K4me3, H3K27me3 and H3K36me3 •Decreases histone methyltransferases SMYD3, EZH2 and NSD1	Induces epigenetic alterations	[53]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2010	Triptolide	RPMI8226 cells	Histone	-0–160 nM triptolide for 48 h		<ul style="list-style-type: none"> •Triptolide decreases histone H3K9me3 and H3K27me3 and downregulates histone methyltransferase SUV39H1 and EZH2 	Induces epigenetic alterations by regulating histone lysine methylation	[124]
2011	Tien-Hsien Liquid	NB4 cells	DNA	-0–3 mg/mL Tien-Hsien Liquid for 72 h		<ul style="list-style-type: none"> •Tien-Hsien Liquid downregulates DNMT1 	Influences epigenetic regulation	[125]
2012	Triptolide	RPMI8226 cells	Histone	-50, 100, and 150 nM triptolide for 48 h		<ul style="list-style-type: none"> •Triptolide suppresses the expression of H3K4me2, H3K9me2 and H3K36me2 and alters the expression of histone demethylase LSD1 and JMJD2B 	Restores epigenetic changes by regulating the histone demethylases LSD1 and JMJD2B	[98]
2015	Triptolide	KM3 cells	Histone	-0–160 nM triptolide for 48 h		<ul style="list-style-type: none"> •Triptolide blocks the accumulation of H3K4me3 on c-Myc and VEGFA promoters 	Decreases the expression of c-Myc and VEGFA genes	[102]
2016	<i>Acanthopanax senticosus</i>	HL-60 and HL60/ADM cells	Histone	<ul style="list-style-type: none"> •100 µg/mL <i>Acanthopanax senticosus</i> for 6 h •100 µg/mL <i>Acanthopanax senticosus</i> for 0–24 h 		<ul style="list-style-type: none"> •<i>Acanthopanax senticosus</i> decreases HDAC enzyme activity •Increases histone ac-H3 	Induces apoptosis of leukemia cells, cell cycle arrest, and FasL expression by promoting histone H3 acetylation	[126]
2020	Zaluzanin D	PMA differentiated human monocytic THP-1 cells	DNA	-0.35 mM zaluzanin D for 24 h		<ul style="list-style-type: none"> •Zaluzanin D reduces hypomethylation of the <i>MMP9</i> gene promoter region caused by PMA activation 	Influences the epigenetic machinery	[55]
2021	Z-ligustilide	Acute myeloid leukemia cells	Histone	-50 µM Z-ligustilide for 1 h -50 µM Z-ligustilide for 6 h		<ul style="list-style-type: none"> •Z-ligustilide increases the enrichment of ac-H3 (K9/14) in the Nur77 and NOR-1 promoters •Increases p300 acetyltransferase and decreases HDACs, including HDAC1 and HDAC4/5/7 and MTA1, recruitment to the Nur77 promoter region 	Restores the expression of both Nur77 and NOR-1	[56]
Other chronic diseases	Parthenolide	J86P + cells	Histone	-5 and 10 µM parthenolide for 24 h		<ul style="list-style-type: none"> •Parthenolide inhibits HDAC1 and increases dimethylation level of H3 (K9/K4) on p21 and cyclin D1 promoters 	Epigenetically modulates p21 and cyclin D1 expression	[47]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2019	Moringa isothiocyanate	JB6P+ cells	DNA	•2.5 µM Moringa isothiocyanate and/or 10 ng/mL 12-O-tetradecanoylphorbol-13-acetate for 5 days	•Moringa isothiocyanate reverses methylation changes in those genes (hyper- or hypomethylation) that occur in response to TPA	Affects the progression of skin carcinogenesis	[40]
2015	Esculetin	Type 2 diabetic rats	Histone	•50 and 100 mg/kg/day esculetin for 2 weeks	•Inhibits H3K4me2, H3K36me2, H3K79me2, H3S10ph, H3S28ph, H3T3ph, H3K27ac and H3K56ac and decreases H2AK119ub and H2BK120ub in hearts of IR and type 2 diabetic rats	Restores normal levels of allowed PTMs and H2A/H2Bub in the hearts of IR and diabetic hearts	[106]
2017	Esculetin	Type 2 diabetic rats	Histone	•50 and 100 mg/kg/day esculetin for 2 weeks	•Esculetin reverses the modification in H2BK120ub and decreases the mRNA levels of Usp16 and Usp22	Intervenes H2Bub system	[33]
2017	Esculetin	Type 2 diabetic rats	Histone	•50 mg/kg/day esculetin for 6 weeks	•Esculetin reduces H3K9ac H2AK119ub and H2BK120ub level	Influences epigenetic regulation	[107]
2021	Naringenin and Hesperetin	INS-1 cells and C57BLKS/Lep rd mice	Histone	•Cell: 100 µM naringenin or hesperetin for 24 h •Mice: 50 mg/kg/day naringenin or 50 mg/kg/day hesperetin for 6 weeks	•Naringenin and hesperetin suppress the acetylation of H3K18 and H3K27 and inhibit the activity of p300, and hesperetin suppresses H3K27 acetylation in the transcriptional regulatory region of <i>Txnip</i> gene in INS-1 cells •Inhibit the acetylation of H3K18 and H3K27 in the islets of the C57BLKS/Lep rd mouse	Reduces the expression of TXNIP	[41]
2020	Hesperetin	RAW 264.7 cells	Histone	•100 µM hesperetin overnight	•Suppresses the acetylation of RelA/p65 by inducing SIRT1 expression	Reduces NF-κB activity	[127]
2022	Kaempferol	3T3-L1 cells	Histone	•100 µM kaempferol	•Kaempferol decreases H3K27me3 deposition in the promoter region of <i>Adipoq</i> , <i>Fabp4</i> , and <i>Lpl</i> genes	Suppresses the expression of PPARγ target genes (<i>Adipoq</i> , <i>Fabp4</i> , and <i>Lpl</i>)	[38]
2020	<i>Bacopa monniera</i> extraction	Male Swiss albino mice	DNA; Histone	•120 mg/kg <i>Bacopa monniera</i> extract	•Reduces the expression of HDACs, and decreases the activity of DNMT and HDAC enzyme and global DNA methylation	Reverses epigenetic changes in scopolamine induced amnesia as well as able to recover levels of synaptic proteins	[128]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2019	Piperine	3T3-L1 cells	Histone	•50 μ M for piperine 8 days	<ul style="list-style-type: none"> •Piperine decreases the enrichment of H3K27me3, PPARγ, and H3K9ac, and increase EZH2 	Augments the expression of Ezh2-associated lipolytic genes	[48]
2021	<i>Sophora flavescens</i> (SF)-F2	PBMCs	DNA	•22.5 μ g/mL <i>Sophora flavescens</i> (SF)-F2 for 3 days	<ul style="list-style-type: none"> •<i>Sophora flavescens</i> (SF)-F2 combination with dexamethasone downregulates the Foxp3 promoter methylation at CpG 	Counteracts dexamethasone-induced immuno-suppression	[129]
2021	Hydroxysafflor yellow A	hBMSCs	Histone	•10 μ M hydroxysafflor yellow A for 48 h	<ul style="list-style-type: none"> •Hydroxysafflor yellow A increases the protein level of KDM7A and decreases the occupancy of H3K27me2 on beta-catenin promoter 	Increases β -catenin expression	[35]
2020	Astragalus polysaccharide	Specific pathogen-free Female Sprague–Dawley rats	DNA	•150 mg/kg/day astragalus polysaccharide for 8 weeks	<ul style="list-style-type: none"> •Astragalus polysaccharide alters the DNA methylation group of the colon epithelium and induces promoter DNA methylation changes in genes involved in calcium homeostasis, osteocast/osteoblast balance, Wnt signaling, and hormone-related processes 	Influences epigenetic regulation	[130]
2011	Multiglycosides of <i>Tripterygium wilfordii</i> Hook f extract	68 days male mice	Histone	•7.5–22.5 mg/kg/day multiglycosides of <i>Tripterygium wilfordii</i> Hook f extract for 40 days	<ul style="list-style-type: none"> •Reduces the dimethylation levels of histone H3K9 in germ cells 	Inhibits the process of spermatogenesis	[131]
2020	Qian Yang Yu Yin Granule	The renal damage model of spontaneously hypertensive rats HEK293T cells	DNA; Histone	<ul style="list-style-type: none"> •Mice: 2.1 or 8.4 g/kg/d Qian Yang Yu Yin Granule for 8 weeks •Cell: 0.5 or 10 μg/mL 	<ul style="list-style-type: none"> •Qian Yang Yu Yin Granule suppresses protein expression of NNMT and ac-cortactin and increased protein expression of H3K4me3 •Inhibits the production of NNMT and SAH mRNA, and promotes the production of SAM and SIRT1, and upregulates DNA methylation 	Protects against hypertension-induced renal injury in spontaneously hypertensive rats and inhibited cells proliferation induced by Ang II	[132]
2021	Juglanin	High fat diet-fed mice	Histone	•7.5–30 mg/kg juglanin for 16 weeks	<ul style="list-style-type: none"> •Juglanin suppresses the expression of HDAC3 from mRNA and protein levels 	Suppresses the activation of NF- κ B/HDAC3 signaling in kidney of HFD-challenged mice	[36]

Table 2 (continued)

Year	Extract/component	Studying model/cell line	Epigenetic targets	Dose characteristics	Gene modified/epigenetic alterations	Outcome	References
2012	Yang-Gan-Wan	Hepatic stellate cells isolated from C57Bl/6 and Coll-GFP mice	Histone	•Yang-Gan-Wan for 7 days	•Yang-Gan-Wan suppresses the expression of PRC2 components, EZH2, SUZ12, and EED, and increases H3K4me2 and H3ac at the PPAR γ promoter locus	Prevents and reverses hepatic stellate cell activation	[133]
2020	Sennoside A	HSC-T6 cells	DNA	•10 μ M sennoside A for 48 h	•Sennoside A blunts the activity of DNMT1 in TGF- β 1-treated HSC-T6 cells	Inhibits activation and proliferation of HSC-T6 cells by targeting DNMT1	[109]
2021	Sennoside A	RAW264.7 cells	DNA	•Sennoside A 20 nM for 24 h	•Sennoside A decreases the activity of DNMT1 in LPS-treated RAW264.7 cells and inhibits SOCS1 hypermethylation mediated by DNMT1	Enhances SOCS1 expression	[49]
2014	Luteolin	THP-1 cells	Histone	•3, 6 and 10 μ M luteolin for 48 h	•Luteolin downregulates HAT activity, upregulates HDAC activity and decreases the levels of acetyl CBP/p300 in high-glucose conditions	Affects NF- κ B and p65 activation and interaction between p300 and NF- κ B under hyperglycemic conditions in monocytes	[39]
2017	Osthole	PDLSCs	Histone	•10 μ M osthole for 7 days	•Osthole increases the expression of KAT5, MOZ, MORF and ELP3, and increases the level of acetylation of H3K9 and H3K14	Reverses defective osteogenesis of P-PDLSCs	[46]
2013	Cannabidiol and cannabigerol	HaCaT cells	DNA	•0.5 μ M cannabidiol or 0.5 μ M cannabigerol for 5 days	•Cannabidiol and cannabigerol enhance DNMT1 expression	Increase global DNA methylation levels and decrease the expression of all the genes examined in the differentiated HaCaT cells by increasing the DNA methylation of the <i>keratin 10</i> gene	[29]
2021	Cannabidiol, luteolin, and piceatannol	CPEK cells	DNA	•10 μ M cannabidiol, 25 μ M luteolin, and 25 μ M piceatannol for 8 h	•Increase the percentage of methylation in ccl2 CpG sites	Manage chronic inflammation through nutraceuticals that modulate DNA methylation	[134]
2022	Cooked rhubarb	Young male Sprague–Dawley rats	DNA	•3 g/kg/day cooked rhubarb for 8 weeks	•Regulates the level of DNA methylation and expression of <i>IL-1α</i> and <i>IL-10</i> genes	Reduces pathological tissue damage caused by chronic alcohol exposure	[135]

Acknowledgements

We would like to thank members of the Lau and Xu laboratory for the critical reading of this manuscript.

Author contributions

Y-YW, Y-MX and ATYL contributed to writing—original draft preparation; Y-MX and ATYL contributed to writing—review and editing, supervision, and funding acquisition. All authors read and approved the final manuscript. Y-YW and Y-MX are the joint first authors and contributed equally to this work. All correspondence should be addressed to ATYL.

Funding

This work was supported by the grants from the National Natural Science Foundation of China (Nos. 31771582 and 31271445), the Guangdong Natural Science Foundation of China (No. 2017A030313131), the “Thousand, Hundred, and Ten” Project of the Department of Education of Guangdong Province of China, the Basic and Applied Research Major Projects of Guangdong Province of China (2017KZDXM035 and 2018KZDXM036), the “Yang Fan” Project of Guangdong Province of China (Andy T. Y. Lau-2016; Yan-Ming Xu-2015), and the Shantou Medical Health Science and Technology Plan (200624165260857).

Availability of data and materials

Not applicable.

Declarations**Ethical approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 25 November 2022 Accepted: 8 April 2023

Published online: 13 May 2023

References

- Choi BC, McQueen DV, Puska P, Douglas KA, Ackland M, Campostrini S, et al. Enhancing global capacity in the surveillance, prevention, and control of chronic diseases: seven themes to consider and build upon. *J Epidemiol Commun Health*. 2008;62:391–7.
- Власик Л, Ступницька Г, Сухололюк А. Peculiarities of primary health care organization for patients suffering from chronic obstructive pulmonary disease jointly with coronary heart disease. *Wiad Lek*. 2017;70:466–9.
- Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy—an update from drug design perspective. *Drug Des Devel Ther*. 2017;11:599–616.
- Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. *Cell Metab*. 2014;20:953–66.
- Traboulsi H, Guerrina N, lu M, Maysinger D, Ariya P, Baglolle CJ. Inhaled pollutants: the molecular scene behind respiratory and systemic diseases associated with ultrafine particulate matter. *Int J Mol Sci*. 2017;18:243.
- Xiao Y, Su M, Ou W, Wang H, Tian B, Ma J, et al. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer. *Biomed Pharmacother*. 2019;117:109192.
- Xiao Y, Xu J, Yin W. Aberrant epigenetic modifications of non-coding RNAs in human disease. *Adv Exp Med Biol*. 2018;1094:65–75.
- Xu C, Tian J, Mo B. siRNA-mediated DNA methylation and H3K9 dimethylation in plants. *Protein Cell*. 2013;4:656–63.
- Guo W, Ma H, Wang CZ, Wan JY, Yao H, Yuan CS. Epigenetic studies of chinese herbal medicine: pleiotropic role of DNA methylation. *Front Pharmacol*. 2021;12:790321.
- Yan R, Chen XL, Xu YM, Lau ATY. Epimutational effects of electronic cigarettes. *Environ Sci Pollut Res Int*. 2021;28:17044–67.
- Zheng SC, Widschwendter M, Teschendorff AE. Epigenetic drift, epigenetic clocks and cancer risk. *Epigenomics*. 2016;8:705–19.
- Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. *Cell Metab*. 2019;29:1028–44.
- Hamm CA, Costa FF. Epigenomes as therapeutic targets. *Pharmacol Ther*. 2015;151:72–86.
- <https://mbd.baidu.com/ma/s/pGrbo9rP>. Accessed on 24 February 2023.
- Yen HR, Lai WY, Muo CH, Sun MF. Characteristics of traditional Chinese medicine use in pediatric cancer patients: a nationwide, retrospective, Taiwanese-registry, population-based study. *Integr Cancer Ther*. 2017;16:147–55.
- Dammann RH, Richter AM, Jimenez AP, Woods M, Kuester M, Witharana C. Impact of natural compounds on DNA methylation levels of the tumor suppressor gene RASSF1A in cancer. *Int J Mol Sci*. 2017;18:2160.
- Sreenivasmurthy SG, Liu JY, Song JX, Yang CB, Malampati S, Wang ZY, et al. Neurogenic traditional chinese medicine as a promising strategy for the treatment of Alzheimer’s disease. *Int J Mol Sci*. 2017;18:272.
- Zhou SH, Deng YF, Weng ZW, Weng HW, Liu ZD. Traditional Chinese medicine as a remedy for male infertility: a review. *World J Mens Health*. 2019;37:175–85.
- Hsieh HY, Chiu PH, Wang SC. Histone modifications and traditional Chinese medicinals. *BMC Complement Altern Med*. 2013;13:115.
- Qiao L, Chen W. Atheroprotective effects and molecular targets of bioactive compounds from traditional Chinese medicine. *Pharmacol Res*. 2018;135:212–29.
- Yu F, Kong L, Zou H, Lei X. Progress on the screening and analysis of bioactive compounds in traditional chinese medicines by biological fingerprinting analysis. *Comb Chem High Throughput Screen*. 2010;13:855–68.
- Fu R, Li J, Yu H, Zhang Y, Xu Z, Martin C. The Yin and Yang of traditional Chinese and western medicine. *Med Res Rev*. 2021;41:3182–200.
- Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med*. 2013;11:110–20.
- Zhang HJ, An YT, Liang Y, Yang XJ, Fan YQ, Ren XL. Recent progress on biopharmaceutics of active ingredients in Chinese materia medica under multi-component system. *Chin J Exp Tradit Med Form*. 2019;25:196–202.
- Qiao L, Han M, Gao S, Shao X, Wang X, Sun L, et al. Research progress on nanotechnology for delivery of active ingredients from traditional Chinese medicines. *J Mater Chem B*. 2020;8:6333–51.
- Chhabria SV, Akbarsha MA, Li AP, Kharkar PS, Desai KB. In situ allicin generation using targeted alliinase delivery for inhibition of MIA PaCa-2 cells via epigenetic changes, oxidative stress and cyclin-dependent kinase inhibitor (CDKI) expression. *Apoptosis*. 2015;20:1388–409.
- Jiang H, Yao Q, An Y, Fan L, Wang J, Li H. Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m(6)A/HKDC1 axis and downstream p-JAK2/STAT1/cleaved Capase3 pathway. *Phytomedicine*. 2022;94:153823.
- Lee MJ, Tsai YJ, Lin MY, You HL, Kalyanam N, Ho CT, Pan MH. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. *Phytomedicine*. 2019;57:377–84.
- Pucci M, Rapino C, Di Francesco A, Dainese E, D’Addario C, Maccarrone M. Epigenetic control of skin differentiation genes by phytocannabinoids. *Br J Pharmacol*. 2013;170:581–91.
- Dittharot K, Dakeng S, Suebsakwong P, Suksamrarn A, Patmasiriwat P, Promkan M. Cucurbitacin B induces hypermethylation of oncogenes in breast cancer cells. *Planta Med*. 2019;85:370–8.
- Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. *DNA Cell Biol*. 2013;32:292–7.
- Tian NN, Zheng YB, Li ZP, Zhang FW, Zhang JF. Histone methylatic modification mediates the tumor-suppressive activity of curcumin in hepatocellular carcinoma via an H2A/EZH2 regulatory axis. *J Ethnopharmacol*. 2021;280:114413.
- Kadkol A, Goru SK, Malek V, Gaikwad AB. Esculetin ameliorates vascular perturbation by intervening in the occupancy of H2BK120Ub at At1, At2, Tgf beta 1 and Mcp1 promoter gene in thoracic aorta of IR and T2D rats. *Biomed Pharmacother*. 2017;95:1461–8.

34. Muhammad T, Ikram M, Ullah R, Rehman SU, Kim MO. Hesperetin, a citrus flavonoid, attenuates I β s-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF- κ B signaling. *Nutrients*. 2019;11:648.
35. Wang P, Wang M, Zhuo T, Li Y, Lin W, Ding L, et al. Hydroxysafflor yellow A promotes osteogenesis and bone development via epigenetically regulating beta-catenin and prevents ovariectomy-induced bone loss. *Int J Biochem Cell Biol*. 2021;137:106033.
36. Li Q, Ge C, Tan J, Sun Y, Kuang Q, Dai X, et al. Juglanin protects against high fat diet-induced renal injury by suppressing inflammation and dyslipidemia via regulating NF- κ B/HDAC3 signaling. *Int Immunopharmacol*. 2021;95:107340.
37. Weng JR, Lai IL, Yang HC, Lin CN, Bai LY. Identification of Kazinol Q, a natural product from formosan plants, as an inhibitor of DNA methyltransferase. *Phytother Res*. 2014;28:49–54.
38. Park UH, Hwang JT, Youn H, Kim EJ, Um SJ. Kaempferol antagonizes adipogenesis by repressing histone H3K4 methylation at PPAR γ target genes. *Biochem Biophys Res Commun*. 2022;617:48–54.
39. Kim HJ, Lee W, Yun JM. Luteolin inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes. *Phytother Res*. 2014;28:1383–91.
40. Wang C, Wu R, Sargsyan D, Zheng M, Li S, Yin R, et al. CpG methyl-seq and RNA-seq epigenomic and transcriptomic studies on the preventive effects of Moringa isothiocyanate in mouse epidermal JB6 cells induced by the tumor promoter TPA. *J Nutr Biochem*. 2019;68:69–78.
41. Wang SW, Sheng H, Bai YF, Weng YY, Fan XY, Zheng F, et al. Inhibition of histone acetyltransferase by naringenin and hesperetin suppresses Txnip expression and protects pancreatic beta cells in diabetic mice. *Phytomedicine*. 2021;88:153454.
42. Yu YL, Yu SL, Su KJ, Wei CW, Jian MH, Lin PC, et al. Extended O-6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth. *J Agric Food Chem*. 2010;58:1630–8.
43. Pooladanda V, Bandi S, Mondi SR, Gottumukkala KM, Godugu C. Nimboide epigenetically regulates autophagy and apoptosis in breast cancer. *Toxicol In Vitro*. 2018;51:114–28.
44. Cui Y, Lu C, Kang A, Liu L, Tan S, Sun D, et al. Nordihydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts. *Anticancer Drugs*. 2008;19:487–94.
45. Lu X, Li Y, Yang W, Tao M, Dai Y, Xu J, Xu Q. Inhibition of NF- κ B is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells. *J Biochem Mol Toxicol*. 2021;35:e22621.
46. Sun J, Dong Z, Zhang Y, He X, Fei D, Jin F, et al. Osthole improves function of periodontitis periodontal ligament stem cells via epigenetic modification in cell sheets engineering. *Sci Rep*. 2017;7:5254.
47. Ghantous A, Saikali M, Rau T, Gali-Muhtasib H, Schneider-Stock R, Darwiche N. Inhibition of tumor promotion by parthenolide: epigenetic modulation of p21. *Cancer Prev Res*. 2012;5:1298–309.
48. Park U, Hwang J, Youn H, Kim E, Um S. Piperine inhibits adipocyte differentiation via dynamic regulation of histone modifications. *Phytother Res*. 2019;33:2429–39.
49. Zhu H, Zhao H, Xu S, Zhang Y, Ding Y, Li J, et al. Sennoside A alleviates inflammatory responses by inhibiting the hypermethylation of SOCS1 in CCl $_4$ -induced liver fibrosis. *Pharmacol Res*. 2021;174:105926.
50. Barros TMB, Lima APB, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. *Environ Mol Mutagen*. 2020;61:445–55.
51. Gong Y, Li Y, Lu Y, Li L, Abdolmaleky H, Blackburn GL, Zhou JR. Bioactive tanshinones in *Salvia miltiorrhiza* inhibit the growth of prostate cancer cells in vitro and in mice. *Int J Cancer*. 2011;129:1042–52.
52. Yan Y, Zhao J, Cao C, Jia Z, Zhou N, Han S, et al. Tetramethylpyrazine promotes SH-SY5Y cell differentiation into neurons through epigenetic regulation of Topoisomerase II β . *Neuroscience*. 2014;278:179–93.
53. Zhao F, Chen Y, Zeng L, Li R, Zeng R, Wen L, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. *Eur J Pharmacol*. 2010;646:1–11.
54. Shi F, Li Y, Han R, Fu A, Wang R, Nusbaum O, et al. Valerian and valeric acid inhibit growth of breast cancer cells possibly by mediating epigenetic modifications. *Sci Rep*. 2021;11:2519.
55. Cheeran V, Munuswamy-Ramanujam G. Sesquiterpene lactone Zalu-zanin D alters MMP-9 promoter methylation in differentiated THP-1 monocytic cells and down regulates inflammatory cytokines IL-1 beta and TNF-alpha. *Int Immunopharmacol*. 2020;87:106803.
56. Wang C, Liu G, Dou G, Yang Y, Chen L, Ma H, et al. Z-Ligustilide selectively targets AML by restoring nuclear receptors Nur77 and NOR-1-mediated apoptosis and differentiation. *Phytomedicine*. 2021;82:153448.
57. Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E, Theocharis S. Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. *Tumor Biol*. 2014;35:61–71.
58. Yuan Z, Chen S, Gao C, Dai Q, Zhang C, Sun Q, et al. Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy. *Bioorg Chem*. 2019;87:200–8.
59. Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. *J Breast Cancer*. 2013;16:23–31.
60. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. *Trends Genet*. 2003;19:286–93.
61. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor. *Brain Pathol*. 2016;26:3–17.
62. Gutmann DH, Kettenmann H. Microglia/brain macrophages as central drivers of brain tumor pathobiology. *Neuron*. 2019;104:442–9.
63. Chaudhuri AR, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. *Nat Rev Mol Cell Biol*. 2017;18:610–21.
64. Ye J, Zhang Y, Liang W, Huang J, Wang L, Zhong X. UHRF1 is an independent prognostic factor and a potential therapeutic target of esophageal squamous cell carcinoma. *J Cancer*. 2017;8:4027–39.
65. Sitarek P, Kowalczyk T, Santangelo S, Biaas AJ, Toma M, Wieczfinska J, et al. The extract of *Leonurus sibiricus* transgenic roots with AtPAP1 transcriptional factor induces apoptosis via DNA damage and down regulation of selected epigenetic factors in human cancer cells. *Neurochem Res*. 2018;43:1363–70.
66. Skala E, Toma M, Kowalczyk T, Sliwinski T, Sitarek P. *Rhaponticum carthamoides* transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage. *Cytotechnology*. 2018;70:1585–94.
67. Zych M, Stec K, Bąblewska A, Pilis K. Importance of diet in reducing cancer incidence in Poland: a review. *Rocz Panstw Zakl Hig*. 2019;70:337–45.
68. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, et al. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. *Int J Oncol*. 2008;33:485–91.
69. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. *Nat Rev Cancer*. 2005;5:42–50.
70. Yin T, Zhao ZB, Guo J, Wang T, Yang JB, Wang C, et al. Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. *Cancer Res*. 2019;79:3431–44.
71. Gong Y, Li Y, Abdolmaleky HM, Li L, Zhou JR. Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. *PLoS ONE*. 2012;7:e33656.
72. Yan C, Sun C, Lu D, Zhao T, Ding X, Zamir I, et al. Estimation of associations between MMP9 gene polymorphisms and breast cancer: evidence from a meta-analysis. *Int J Biol Markers*. 2022;37:13–20.
73. Wu HT, Lin J, Liu YE, Chen HF, Hsu KW, Lin SH, et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. *Phytomedicine*. 2021;81:153437.
74. Wu HT, Liu YE, Hsu KW, Wang YF, Chan YC, Chen Y, Chen DR. MLL3 induced by luteolin causes apoptosis in tamoxifen-resistant breast cancer cells through H3K4 monomethylation and suppression of the PI3K/AKT/mTOR pathway. *Am J Chin Med*. 2020;48:1221–41.
75. Lu J, Zhang X, Shen T, Ma C, Wu J, Kong H, et al. Epigenetic profiling of H3K4Me3 reveals herbal medicine Jinfukang-induced epigenetic alteration is involved in anti-lung cancer activity. *Evid Based Compl Alternat Med*. 2016;2016:7276161.

76. Estrada-Martínez LE, Moreno-Celis U, Cervantes-Jiménez R, Ferriz-Martínez RA, Blanco-Labra A, García-Gasca T. Plant lectins as medical tools against digestive system cancers. *Int J Mol Sci.* 2017;18:1403.
77. Li Y, Xu Q, Yang W, Wu T, Lu X. Oleonic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells. *Gene.* 2019;712:143956.
78. Wang SW, Sheng H, Zheng F, Zhang F. Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis. *Phytomedicine.* 2021;84:153499.
79. Serra S, Chetty R. p16. *J Clin Pathol.* 2018;71:853–8.
80. Qiu Z, Andrijaskaite K, Morris J, Wargovich MJ. Disruption of epigenetic silencing in human colon cancer cells lines utilizing a novel supercritical CO₂ extract of neem leaf (*Azadirachta indica*). *Anticancer Res.* 2019;39:5473–81.
81. Bujak R, Dagher E, Rybka J, Koslinski P, Markuszewski MJ. Metabolomics in urogenital cancer. *Bioanalysis.* 2011;3:913–23.
82. Vargas-Rondón N, Villegas VE, Rondón-Lagos M. The Role of chromosomal instability in cancer and therapeutic responses. *Cancers.* 2017;10:4.
83. Tamgue O, Chai CS, Hao L, Zambé JC, Huang WW, Zhang B, et al. Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. *Asian Pac J Cancer Prev.* 2013;14:5663–9.
84. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. *J Hematol Oncol.* 2020;13:104.
85. Yamaguchi H, Hung MC. Regulation and role of EZH2 in cancer. *Cancer Res Treat.* 2014;46:209–22.
86. Tamgue O, Lei M. Triptolide promotes senescence of prostate cancer cells through histone methylation and heterochromatin formation. *Asian Pac J Cancer Prev.* 2017;18:2519–26.
87. Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. *Nature.* 2007;449:731–4.
88. Yang B, Yang J, Bai J, Pu P, Liu J, Wang F, Ruan B. Suv39h1 protects from myocardial ischemia-reperfusion injury in diabetic rats. *Cell Physiol Biochem.* 2014;33:1176–85.
89. Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, et al. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. *Cancer Prev Res.* 2014;7:1186–97.
90. Su ZY, Khor TO, Shu L, Lee JH, Saw CLL, Wu TY, et al. Epigenetic reactivation of Nrf2 in murine prostate cancer TRAMP C1 cells by natural phytochemicals Z-ligustilide and radix angelica sinensis via promoter CpG demethylation. *Chem Res Toxicol.* 2013;26:477–85.
91. Ciccone DN, Su H, Hevi S, Gay F, Lei H, Bajko J, et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. *Nature.* 2009;461:415–8.
92. Lee YK, Lim J, Yoon SY, Joo JC, Park SJ, Park YJ. Promotion of cell death in cisplatin-resistant ovarian cancer cells through KDM1B-DCLRE1B modulation. *Int J Mol Sci.* 2019;20:2443.
93. Moser-Katz T, Joseph NS, Dhodapkar MV, Lee KP, Boise LH. Game of Bones: how myeloma manipulates its microenvironment. *Front Oncol.* 2021;10:625199.
94. Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. *J Biol Chem.* 2009;284:19867–77.
95. Bernard BJ, Nigam N, Burkitt K, Saloura V. SMYD3: a regulator of epigenetic and signaling pathways in cancer. *Clin Epigenetics.* 2021;13:45.
96. Yang C, Wang K, Liang Q, Tian TT, Zhong Z. Role of NSD1 as potential therapeutic target in tumor. *Pharmacol Res.* 2021;173:105888.
97. Krossa I, Strub T, Aplin AE, Ballotti R, Bertolotto C. Lysine methyltransferase NSD1 and cancers: any role in melanoma? *Cancers.* 2022;14:4865.
98. Wen L, Chen Y, Zeng LL, Zhao F, Li R, Liu Y, Zhang C. Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B. *Acta Pharmacol Sin.* 2012;33:109–19.
99. Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. *Oncotarget.* 2017;8:73372–86.
100. Shin S, Janknecht R. Diversity within the JMJD2 histone demethylase family. *Biochem Biophys Res Commun.* 2007;353:973–7.
101. Fujiwara K, Fujita Y, Kasai A, Onaka Y, Hashimoto H, Okada H, Yamashita T. Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse. *Transl Psychiatry.* 2016;6:e766.
102. Wen L, Chen Y, Zeng LL, Zhao F, Yi S, Yang LJ, et al. Triptolide induces cell apoptosis by targeting H3K4me3 and downstream effector proteins in KM3 multiple myeloma cells. *Curr Pharm Biotechnol.* 2015;17:147–60.
103. McFee RM, Rozell TG, Cupp AS. The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development. *Cell Tissue Res.* 2012;349:635–47.
104. Kadakol A, Malek V, Goru SK, Pandey A, Bagal S, Gaikwad AB. Esculetin attenuates alterations in Ang II and acetylcholine mediated vascular reactivity associated with hyperinsulinemia and hyperglycemia. *Biochem Biophys Res Commun.* 2015;461:342–7.
105. Tikoo K, Meena RL, Kabra DG, Gaikwad AB. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. *Br J Pharmacol.* 2008;153:1225–31.
106. Kadakol A, Malek V, Goru SK, Pandey A, Gaikwad AB. Esculetin reverses histone H2A/H2B ubiquitination, H3 dimethylation, acetylation and phosphorylation in preventing type 2 diabetic cardiomyopathy. *J Funct Foods.* 2015;17:127–36.
107. Kadakol A, Malek V, Goru SK, Pandey A, Gaikwad AB. Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications. *Indian J Pharmacol.* 2017;49:348–56.
108. Moran-Salvador E, Mann J. Epigenetics and Liver Fibrosis. *Cell Mol Gastroenterol Hepatol.* 2017;4:125–34.
109. Zhu H, He C, Zhao H, Jiang W, Xu S, Li J, et al. Sennoside A prevents liver fibrosis by binding DNMT1 and suppressing DNMT1-mediated PTEN hypermethylation in HSC activation and proliferation. *Faseb J.* 2020;34:14558–71.
110. Zheng L, Chen X, Guo J, Sun H, Liu L, Shih DQ, Zhang X. Differential expression of PTEN in hepatic tissue and hepatic stellate cells during rat liver fibrosis and its reversal. *Int J Mol Med.* 2012;30:1424–30.
111. Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. *J Exp Med.* 2004;199:1701–7.
112. Cui Y, Lu C, Liu L, Sun D, Yao N, Tan S, et al. Reactivation of methylation-silenced tumor suppressor gene p16INK4a by nordihydroguaiaretic acid and its implication in G1 cell cycle arrest. *Life Sci.* 2008;82:247–55.
113. Bozkurt E, Atmaca H, Kisim A, Uzunoglu S, Uslu R, Karaca B. Effects of thymus serpyllum extract on cell proliferation, apoptosis and epigenetic events in human breast cancer cells. *Nutr Cancer.* 2012;64:1245–50.
114. Yao CJ, Chow JM, Yang CM, Kuo HC, Chang CL, Lee HL, et al. Chinese herbal mixture, tien-hsien liquid, induces G2/M cycle arrest and radio-sensitivity in MCF-7 human breast cancer cells through mechanisms involving DNMT1 and Rad51 downregulation. *Evid Based Complement Alternat Med.* 2016;2016:3251046.
115. Ma H, Li L, Dou G, Wang C, Li J, He H, et al. Z-ligustilide restores tamoxifen sensitivity of ER alpha negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ER alpha. *Oncotarget.* 2017;8:29328–45.
116. Gospodinova ZI, Zupkó I, Bózsity N, Manova VI, Georgieva MS, Todinova SJ, et al. *Cotinus coggygria* Scop. induces cell cycle arrest, apoptosis, genotoxic effects, thermodynamic and epigenetic events in MCF7 breast cancer cells. *Z Naturforsch C J Biosci.* 2020;76:129–40.
117. Kovi RC, Bhusari S, Mav D, Shah RR, Ton TV, Hoenerhoff MJ, et al. Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. *Arch Toxicol.* 2019;93:2219–35.
118. Lin ZH, Chan YF, Pan MH, Tung YC, Su ZY. Aged citrus peel (chenpi) prevents acetaminophen-induced hepatotoxicity by epigenetically regulating Nrf2 pathway. *Am J Chin Med.* 2019;47:1833–51.
119. Han R, Nusbaum O, Chen X, Zhu Y. Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. *Mol Ther Oncolytics.* 2020;19:8–18.

120. Zain SNDM, Omar WAW. *Phyllanthus debilis* methanolic extract reduces the viability of human colorectal adenocarcinoma (HT-29) cells and increases LINE-1 and Alu DNA methylation. *Pertanika J Trop Agric Sci*. 2022;45:25–36.
121. Huang Y, Song H, Hu H, Cui L, You C, Huang L. Trichosanthin inhibits DNA methyltransferase and restores methylation-silenced gene expression in human cervical cancer cells. *Mol Med Rep*. 2012;6:872–8.
122. Zhao K, Wang W, Yu X, Zhou X, Shi Q, Hu Y. Triptolide-induced apoptosis of androgen-independent prostatic cancer (AIPC) via modulation of histone methylation. *Drug Dev Res*. 2012;73:222–8.
123. Huang EC, Zhao Y, Chen G, Baek SJ, McEntee MF, Minkin S, et al. Zylflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. *BMC Complement Altern Med*. 2014;14:68.
124. Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. *Toxicology*. 2010;267:70–9.
125. Yao CJ, Yang CM, Chuang SE, Yan JL, Liu CY, Chen SW, et al. Targeting PML-RAR α and oncogenic signaling pathways by Chinese herbal mixture tien-hsien liquid in acute promyelocytic leukemia NB4 Cells. *Evid Based Complement Alternat Med*. 2011;2011:984154.
126. Wang Y, Zhong H, Chen FY, Zhang MY, Cai JY, Zhong JH. A preliminary study on epigenetic regulation of *Acanthopanax senticosus* in leukemia cell lines. *Exp Hematol*. 2016;44:466–73.
127. Wang SW, Wang W, Sheng H, Bai YF, Weng YY, Fan XY, et al. Hesperetin, a SIRT1 activator, inhibits hepatic inflammation via AMPK/CREB pathway. *Int Immunopharmacol*. 2020;89:107036.
128. Goyal K, Konar A, Kumar A, Koul V. Bacosides encapsulated in lactoferrin conjugated PEG-PLA-PCL-OH based polymersomes act as epigenetic modulator in chemically induced amnesia. *Neurochem Res*. 2020;45:796–808.
129. Song Y, Wang ZZ, Wang L, Faybusovich P, Srivastava K, Liu C, et al. *Sophora flavescens* alkaloids and corticosteroid synergistically augment IL-10/IL-5 ratio with Foxp3-Gene-epigenetic modification in asthma PBMCs. *J Asthma Allergy*. 2021;14:1559–71.
130. Liu J, Liu J, Duan S, Liu L, Zhang G, Peng X. Reprogrammed epigenetic landscape-prophesied functions of bioactive polysaccharides in alleviating diseases: a pilot study of DNA methylome remodeling in astragalus polysaccharide (APS)-improved osteoporosis in a Rat Model. *J Agric Food Chem*. 2020;68:15449–59.
131. Xiong J, Wang H, Guo G, Wang S, He L, Chen H, Wu J. Male germ cell apoptosis and epigenetic histone modification induced by *Tripterygium wilfordii* Hook F. *PLoS ONE*. 2011;6:e20751.
132. Zhang SF, Mao XJ, Jiang WM, Fang ZY. Qian Yang Yu Yin Granule protects against hypertension-induced renal injury by epigenetic mechanism linked to Nicotinamide N-Methyltransferase (NNMT) expression. *J Ethnopharmacol*. 2020;255:112738.
133. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect. *Hepatology*. 2012;55:1271–81.
134. Massimini M, Dalle Vedove E, Bachetti B, Di Pierro F, Ribecco C, D'Addario C, Pucci M. Polyphenols and cannabidiol modulate transcriptional regulation of Th1/Th2 inflammatory genes related to canine atopic dermatitis. *Front Vet Sci*. 2021;8:606197.
135. Zhao X, Zhu S, Li J, Long D, Wan M, Tang W. Epigenetic changes in inflammatory genes and the protective effect of cooked rhubarb on pancreatic tissue of rats with chronic alcohol exposure. *Biomed Pharmacother*. 2022;146:112587.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com